I know, but it is what you told us and that is what is written in your action plan. However, we know that the current mechanism for approving drugs does not enable us to detect most of the adverse side effects of the drugs. However, your plan and your strategy for the post-market analysis for 2007-2012, provides that Health Canada new plan is intended to modernize the system, as you said, of regulations in Canada. At the same time, you will be guided by, and you will even apply the standards set by the international conference on harmonization of technical requirements. We know very well that this plan, that you used as a model, will shorten the drug approval process by bringing the protection standards down to the lowest common denominator. Thus, you want to develop, as they did, a unique set of regulations for all clinical trials.
I was alarmed by the fact that the current drug approval mechanism does not enable us to detect most of the adverse side effects. However, if you want to take the ICH as a model, you will, just as it did and shorten the approval process for certain drugs. You know that the pharmaceutical companies would like to do all the marketing of certain drugs because it is more profitable for them. I do not think, therefore, that you are going in the right direction, if you use the ICH as a model.